In 1988, when the World Health Assembly committed to eradicating polio by the year 2000, the virus was paralysing an estimated 350,000 children a year across more than 125 countries. The campaign that followed became one of the most ambitious public health efforts in history. It mobilised some 20 million volunteers and more than $20 billion. By most measures it has been a remarkable success: wild poliovirus types 2 and 3 have been eradicated, and cases have fallen by more than 99 percent.

Yet the target date has slipped again and again, and wild type 1 still circulates in the borderlands of Pakistan and Afghanistan. Outbreaks of vaccine-derived poliovirus also keep appearing in places that had long been declared free of the disease. The final fraction of a percent has proven more resistant than the ninety-nine that came before it, and far more expensive for each case prevented.

This is not a failure of biology or technology. The vaccines work, the surveillance systems are among the most sophisticated in global health, and the epidemiology is well understood. What polio's endgame exposes are the limits that technical capability cannot overcome on its own: political suspicion, armed conflict, and unresolved questions about what single-disease campaigns leave behind. These lessons reach well beyond polio, because every future elimination effort will eventually arrive at its own last mile.

In 2003, political and religious leaders in several northern Nigerian states, most prominently Kano, suspended oral polio vaccination. They acted amid claims that the drops contained anti-fertility agents or HIV. The boycott lasted roughly a year. By the time immunisation resumed, Nigerian poliovirus had spread to around twenty previously polio-free countries, reaching as far as Yemen and Indonesia. Containing it cost hundreds of millions of dollars.

The rumours did not arise in a vacuum. Northern Nigeria had a long memory of marginalisation by federal authorities. It also had recent grievances against Western pharmaceutical companies, including Pfizer's controversial 1996 trial of an experimental antibiotic in Kano during a meningitis epidemic. Outsiders arrived offering free drops for a single disease while local clinics lacked basic medicines. In that setting, suspicion was a reasonable way to interpret events, not simply ignorance.

Pakistan's experience took a darker turn. In 2011, the CIA used a sham hepatitis B vaccination campaign in Abbottabad to try to obtain DNA from Osama bin Laden's household. Once exposed, the operation gave militant groups a ready-made story. The Pakistani Taliban banned vaccination in parts of the tribal areas in 2012, and attacks on vaccinators followed. By 2014 Pakistan recorded more than 300 wild polio cases, its highest total in over a decade.

What these cases share is that vaccine refusal can work as political speech. Communities use the one intervention the state and its international partners visibly care about as leverage. They protest drone strikes, demand electricity or roads, or signal distrust of distant governments. India faced similar resistance in parts of western Uttar Pradesh. It overcame that resistance through thousands of locally recruited community mobilisers, partnerships with religious leaders, and attention to wider health needs.

The lesson is that trust is infrastructure in its own right. It is built slowly and destroyed quickly, often by actors far outside the health sector. Eradication programmes have often treated refusal as a communications problem to be fixed with better messaging. In reality, refusal frequently reflects real grievances about governance, sovereignty, and neglect, and no amount of technical precision can get around those.

Takeaway

Vaccine refusal is often a political message delivered through the one channel communities know will be heard. Treating it only as misinformation misreads the problem and the solution.

The idea that wars might pause for vaccination has a surprising history. In 1985, UNICEF's James Grant helped negotiate 'days of tranquillity' in El Salvador's civil war. Government and rebel forces halted fighting so that children could be immunised. The model was later repeated in Lebanon, Sudan, Afghanistan, and elsewhere. It established an unusual norm: child immunisation could occupy neutral ground even during active hostilities.

That norm was tested again in 2024. Poliovirus was detected in Gaza, and a ten-month-old child was paralysed, the first case there in roughly twenty-five years. Negotiated humanitarian pauses allowed teams to reach more than half a million children in each of two rounds. This was a remarkable logistical feat in a territory where health infrastructure had largely collapsed. Even so, the pauses were fragile, limited to specific areas, and dependent on constant diplomatic pressure.

Where formal pauses are impossible, programmes improvise. In northeast Nigeria, large areas fell under Boko Haram's control. Teams vaccinated children at the edges of inaccessible zones and followed military operations into newly retaken settlements. They used satellite imagery to estimate populations in places no surveyor could visit. In Syria and Somalia, vaccinators recruited from within contested communities often worked discreetly and without visible branding, because ties to outside organisations could prove fatal.

These measures carry real costs. In Pakistan, more than a hundred polio workers and security escorts have been killed since 2012, many of them women earning modest daily stipends. Armed escorts protect teams, but they can also blur the line between health workers and state security forces. That reinforces the very perception that made the workers targets. Every adaptation buys access while potentially wearing away the neutrality that access ultimately depends on.

Conflict also exposes a deeper mismatch. Eradication requires near-universal coverage sustained over years. War produces displacement, broken surveillance, and populations that appear and disappear unpredictably. A single missed pocket of children can restart transmission across borders. In 2016, wild polio was discovered in Borno, two years after Nigeria's last recorded case. The discovery showed how silently the virus can persist where surveillance cannot reach.

Takeaway

Every workaround that buys access in a war zone spends some of the neutrality that made access possible in the first place. Health operations in conflict are always drawing down a limited reserve.

Over nearly four decades, the Global Polio Eradication Initiative built something no other health programme has. It includes a worldwide network of laboratories, surveillance systems for acute flaccid paralysis, environmental sewage sampling, and detailed planning that reaches individual households. In many low-income countries, polio funding has paid for a substantial share of WHO's country-level staff. It has also supplied much of the day-to-day operational backbone of immunisation.

Supporters point to concrete benefits. When Ebola reached Lagos in 2014, Nigeria repurposed its polio emergency operations centre and trained staff to trace contacts. That helped contain the outbreak in Africa's largest city. Polio networks later supported measles campaigns, COVID-19 vaccine rollout, and broader disease surveillance across sub-Saharan Africa. In this view, eradication spending created public health capacity that would otherwise never have existed.

Critics see a more mixed record. Repeated house-to-house campaigns pulled health workers away from routine primary care. Per diem payments for campaign days sometimes made polio work more attractive than clinic duty. Some communities were offered polio drops again and again while measles vaccine or basic medicines stayed scarce, and they read the programme's narrow focus as a sign of hidden motives. Parallel structures could crowd out national health systems instead of strengthening them.

The question of what happens when funding ends has turned this debate into an urgent planning problem. Polio-free regions are moving away from GPEI support, and donor budgets are tightening. Countries now risk losing surveillance and laboratory functions that were never fully absorbed into domestic health budgets. Assets built as temporary scaffolding have quietly become structural, and removing them threatens capacities far beyond polio.

For future campaigns against measles, malaria, or other diseases, this becomes a design choice to make at the outset, not an afterthought. Julio Frenk and others have long argued for 'diagonal' approaches, which pursue disease-specific goals through investments that deliberately strengthen shared systems. Polio suggests that transition planning belongs in year one, not year thirty. A lasting legacy has to be built on purpose; it will not appear on its own.

Takeaway

Temporary scaffolding has a way of becoming load-bearing without anyone deciding it should. Any time-limited health campaign should plan from the start for what it will leave behind.

Polio's endgame has become a stress test for global health itself. The campaign has shown what coordinated international action can achieve. It has eliminated two of three wild strains and spared an estimated 20 million people from paralysis. It has also revealed exactly where technical excellence runs out.

In Nigeria, Pakistan, Afghanistan, and Gaza, the barriers are social and political at their core. Trust has been eroded by intelligence operations and neglect, access depends on armed actors, and health systems are shaped by priorities set far away. Jim Yong Kim argued that global health is ultimately a problem of delivery, not discovery, and polio is one of the clearest illustrations.

The last mile is not simply the hardest stretch of the same road. It is a different road altogether, running through governance, sovereignty, and relationships. Every future elimination campaign will reach it eventually, and polio suggests planning for it from the very first day.